


Application No.: 10/208,650

1

Docket No.: 49165C3(71994)

Express Mail Label No. ZV51791600705



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jesper Wengel et al.

Application No.: 10/208,650

Confirmation No.: 3515

Filed: July 29, 2002

Art Unit: 1637

For: OLIGONUCLEOTIDE ANALOGUES

Examiner: J. Riley

MS Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

AMENDMENT UNDER 37 C.F.R. §1.312

Applicants respectfully request that the following amendment be entered prior to issuance of the above-captioned application. The present amendment is being filed prior to payment of the issue fee.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 14 of this paper.



Application No. (if known): 10/208,650

Attorney Docket No.: 49165C3(71994)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV517916007US in an envelope addressed to:

MS Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on December 20, 2004
Date

Signature

Patricia Barnes

Typed or printed name of person signing Certificate

Registration Number, if applicable

(817) 438-4444
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Amendment Under 37 CFR §1.312 (14 pages)

Application No.: 10/208,650


2

Docket No.: 49165C3(71994)

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

157. (previously presented) A nucleoside analogue (hereinafter termed "LNA") of the general formula I



wherein X is selected from -O-;

B is selected from hydrogen, hydroxy, optionally substituted C₁₋₄ alkoxy, optionally substituted C₁₋₄-alkyl, optionally substituted C₁₋₄-acyloxy, nucleobases, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands;

P designates a 5'-terminal group optionally including the substituent R⁵;

one of the substituents R², R^{2*}, R³, and R^{3*} is a group P* which designates an internucleoside linkage or a 3'-terminal group;

one pair of non-geminal substituents R^{4*}, and R^{2*}, designating a biradical selected from the following group:

- (a) $-(CR^*R^*)_r-O-(CR^*R^*)_s-$ wherein r is 0 (zero) and s is greater than 1, or s is 0 (zero) and r is greater than 1,

and further wherein each R* is independently selected from hydrogen, halogen, hydroxy, mercapto, amino, optionally substituted C₁₋₆-alkoxy, optionally substituted C₁₋₆-alkyl, DNA

Application No.: 10/208,650

3


Docket No.: 49165C3(71994)

intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands; and

each of the substituents R^{1*} , R^2 , R^3 , R^5 , and R^{5*} , which are present and not involved in P, P' is independently selected from hydrogen, optionally substituted C_{1-12} -alkyl, optionally substituted C_{2-12} -alkenyl, optionally substituted C_{2-12} -alkynyl, hydroxy, C_{1-12} -alkoxy, C_{2-12} -alkenyloxy, carboxy, C_{1-12} -alkoxycarbonyl, C_{1-12} -alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C_{1-6} -alkyl)amino, carbamoyl, mono- and di(C_{1-6} -alkyl)-amino-carbonyl, amino- C_{1-6} -alkyl-aminocarbonyl, mono- and di(C_{1-6} -alkyl)amino- C_{1-6} -alkyl-aminocarbonyl, C_{1-6} -alkyl-carbonylamino, carbamido, C_{1-6} -alkanoyloxy, sulphonyl, C_{1-6} -alkylsulphonyloxy, nitro, azido, sulphonyl, C_{1-6} -alkylthio, halogen, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, where aryl and heteroaryl may be optionally substituted;

and basic salts and acid addition salts thereof.

158. (previously presented) A nucleoside analogue (hereinafter LNA) of the general formula II



II

wherein the substituent B is selected from nucleobases, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands;

X is selected from -O-;

one of the substituents R^2 , R^3 , and R^{3*} is a group Q^* ;

each of Q and Q^* is independently selected from hydrogen, azido, halogen, cyano, nitro, hydroxy, Prot-O-, Act-O-, mercapto, Prot-S-, Act-S-, C_{1-6} -alkylthio, amino, ProtN(R^H)-, Act-N(R^H)-, mono- or di(C_{1-6} -alkyl)amino, optionally substituted C_{1-6} -alkoxy, optionally substituted

Application No.: 10/208,650

4

Docket No.: 49165C3(71994)

C₁₋₆-alkyl, optionally substituted C₂₋₆-alkenyl, optionally substituted C₂₋₆-alkenyloxy, optionally substituted C₂₋₆-alkynyl, optionally substituted C₂₋₆-alkynyloxy, monophosphate, diphosphate, triphosphate, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, ligands, carboxy, sulphonyl, hydroxymethyl, Prot-O-CH₂-, Act-O-CH₂-, aminomethyl, Prot-N(R^H)-CH₂-, Act-N(R^H)-CH₂-, carboxymethyl, sulphonomethyl, where Prot is a protection group for -OH, -SH, and -NH(R^H), respectively, Act is an activation group for -OH, -SH, and -NH(R^H), respectively, and R^H is selected from hydrogen and C₁₋₆-alkyl;

wherein R^{2*} and R^{4*} together designate a biradical selected from the following group:

- (a) $-(\text{CR}^1\text{R}^2)_r-\text{O}-(\text{CR}^3\text{R}^4)_s-$ wherein r is 0 (zero) and s is greater than 1, or s is 0 (zero) and r is greater than 1,

and further wherein each Rⁱ is independently selected from hydrogen, halogen, hydroxy, mercapto, amino, optionally substituted C₁₋₆-alkoxy, optionally substituted C₁₋₆-alkyl, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands; and

each of the substituents R^{1*}, R^{2*}, R^{3*}, R^{4*}, and R^{5*}, which are not involved in Q, Q^{*}, is independently selected from hydrogen, optionally substituted C₁₋₁₂-alkyl, optionally substituted C₂₋₁₂-alkenyl, optionally substituted C₂₋₁₂-alkynyl, hydroxy, C₁₋₁₂-alkoxy, C₂₋₁₂-alkenyloxy, carboxy, C₁₋₁₂-alkoxycarbonyl, C₁₋₁₂-alkylcarbonyl, formyl, aryl, aryloxy-carbonyl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy-carbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di(C₁₋₆-alkyl)amino, carbamoyl, mono- and di(C₁₋₆-alkyl)-amino-carbonyl, amino-C₁₋₆-alkylaminocarbonyl, mono- and di(C₁₋₆-alkyl)amino-C₁₋₆-alkyl-aminocarbonyl, C₁₋₆-alkylcarbonylamino, carbamido, C₁₋₆-alkanoyloxy, sulphonyl, C₁₋₆-alkylsulphonyloxy, nitro, azido, sulphonyl, C₁₋₆-alkylthio, halogen, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, where aryl and heteroaryl may be optionally substituted;

and basic salts and acid addition salts thereof;

with the proviso that,

Application No.: 10/208,660

5

Docket No.: 49165C3(71994)

any chemical group (including any nucleobase), which is reactive under the conditions prevailing in oligonucleotide synthesis, is optionally functional group protected.

159 (previously presented). A nucleoside analogue according to claim 158, wherein the group B is selected from nucleobases and functional group protected nucleobases.

160 (previously presented). A nucleoside analogue according to any of the claims 158-159, wherein each of the substituents R^{1*} , R^2 , R^3 , R^{3*} , R^5 , and R^{5*} , which are present and not involved in Q, Q^* , is independently selected from hydrogen, optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, hydroxy, C_{1-6} -alkoxy, C_{2-6} -alkenyloxy, carboxy, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkylcarbonyl, formyl, amino, mono- and di(C_{1-6} -alkyl)amino, carbamoyl, mono- and di(C_{1-6} -alkyl)-amino-carbonyl, C_{1-6} -alkylcarbonylamino, carbamido, azido, C_{1-6} -alkanoyloxy, sulphonyl, sulphonyl, C_{1-6} -alkylthio, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, ligands, and halogen, and where R^{N*} , when present and not involved in a biradical, is selected from hydrogen and C_{1-6} -alkyl, with the proviso that any hydroxy, amino, mono(C_{1-6} -alkyl)amino, sulfanyl, and carboxy is optionally protected.

161 (previously presented). A nucleoside analogue according to any of the claims 158, 159, each of the substituents R^{1*} , R^2 , R^3 , R^{3*} , and R^5 , R^{5*} , which are present and not involved in Q^* designate hydrogen.

162 (previously presented). A nucleoside analogue according to any of the claims 158, 159, wherein R^{3*} designates P^* .

163 (previously presented). A nucleoside analogue according to claim 158, wherein Q is independently selected from hydrogen, azido, halogen, cyano, nitro, hydroxy, Prot-O-, mercapto, Prot-S-, C_{1-6} -alkylthio, amino, Prot-N(R^H)-, mono- or di(C_{1-6} alkyl)amino,

optionally substituted C_{1-6} -alkoxy, optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, optionally substituted C_{2-6} alkenyloxy, optionally substituted C_{2-6} -alkynyl, optionally substituted C_{2-6} -alkynyloxy, monophosphate, diphosphate, triphosphate, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, ligands, carboxy, sulphonyl, hydroxymethyl, Prot-O-CH₂-,

Application No.: 10/208,650


6

Docket No.: 49165C3(71994)

aminomethyl, Prot-N(R^H)-CH₂-, carboxymethyl, sulphonomethyl, where Prot is a protection group for -OH, -SH, and -NH(R^H), respectively, and R^H is selected from hydrogen and C₁₋₆-alkyl; and

Q^{*} is selected from hydrogen, azido, halogen, cyano, nitro, hydroxy, Act-O-, mercapto, Act-S-, C₁₋₆-alkylthio, amino, Act-N(R^H)-, mono- or di(C₁₋₆-alkyl)amino, optionally substituted C₁₋₆alkoxy, optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆alkenyl, optionally substituted C₂₋₆alkenyloxy, optionally substituted C₂₋₆alkynyl, optionally substituted C₂₋₆alkynyloxy, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, ligands, carboxy, sulphono, where Act is an activation group for -OH, -SH, and -NH(R^H), respectively, and R^H is selected from hydrogen and C₁₋₆-alkyl.

164 (previously presented) A nucleoside analogue according to claim 158, having the general formula IIa



wherein the substituents Q, B, R^{1*}, R², R^{2*}, R³, R^{3*}, R^{4*}, R⁵, and R^{5*} are as defined in claim 158 provided the nucleoside analogue has a configuration other than α-L.

165 (previously presented) A nucleoside analogue according to claim 164, wherein R^{3*} designates P^{*}.

166. (previously presented) A nucleoside analogue according to claim 165, wherein R² selected from hydrogen, hydroxy, and optionally substituted C₁₋₆-alkoxy, and R^{1*}, R³, R⁵, and R^{5*}, designate hydrogen.

Application No.: 10/208,650


7

Docket No.: 49165C3(71994)

167. (previously presented) A nucleoside analogue according to any of the claims 165 or 166, wherein B is selected from nucleobases.

168. (previously presented) A nucleoside analogue according to claim 167, wherein B is selected from adenine and guanine thymine, cytosine uracil purine, xanthine, diaminopurine, 8-oxo- N^6 -methyladenine, 7-deazaxanthine, 7-deazaguanine, N^4,N^4 -ethanocytosin, N^6,N^6 -ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C^1-C^6)-alkynylcytosine, 2,6-diaminopyrimidine, 2,6-diaminopyrazine, 1-methyl-pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione, 1-methyl-pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanin, and inosine.

169. (previously presented) A nucleoside analogue according to claim 158 of the general formula IIa.



wherein X is -O-;

B is selected from nucleobases, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands;

R^{1*} is a group Q^* ;

each of Q and Q^* is independently selected from hydrogen, azido, halogen, cyano, nitro, hydroxy, Prot-O-, Act-O-, mercapto, Prot-S-, Act-S-, C_{1-6} -alkylthio, amino, Prot-N(R^H)-, Act-N(R^H)-, mono- or di(C_{1-6} -alkyl)amino, optionally substituted C_{1-6} -alkoxy, optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, optionally substituted C_{2-6} -alkenyloxy, optionally substituted C_{2-6} -alkynyl, optionally substituted C_{2-6} -alkynyloxy, monophosphate, diphosphate, triphosphate, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, ligands,

Application No.: 10/208,650

8

Docket No.: 49165C3(71994)

carboxy, sulphono, hydroxymethyl, Prot-O-CH₂-, Act-O-CH₂-, aminomethyl, Prot-N(R^H)-CH₂-, Act-N(R^H)-CH₂-, carboxymethyl, sulphonomethyl, where Prot is a protection group for -OH, -SH, and -NH(R^H), respectively, Act is an activation group for -OH, -SH, and -NH(R^H), respectively, and R^H is selected from hydrogen and C₁₋₆-alkyl;

R^{2*} and R^{4*} together designate a biradical selected from the following group:

- (a) $-(\text{CR}^{\text{r}}\text{R}^{\text{s}})_r\text{O}-(\text{CR}^{\text{r}}\text{R}^{\text{s}})_s-$ wherein r is 0 (zero) and s is greater than 1, or s is 0 (zero) and r is greater than 1,

and further wherein each R^r is independently selected from hydrogen, halogen, hydroxy, mercapto, amino, optionally substituted C₁₋₆-alkoxy, optionally substituted C₁₋₆-alkyl, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands;

each of the substituents R^{1*}, R², R³, R⁵, and R^{5*} is independently selected from hydrogen, optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆-alkenyl, hydroxy, C₁₋₆-alkoxy, C₂₋₆-alkenyloxy, carboxy, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkylcarbonyl, formyl, amino, mono- and di(C₁₋₆-alkyl)amino, carbamoyl, mono- and di(C₁₋₆-alkyl)-amino-carbonyl, C₁₋₆-alkyl-carbonylamino, carbamido, azido, C₁₋₆-alkanoyloxy, sulphono, sulphonyl, C₁₋₆-alkylthio, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, and halogen; and basic salts and acid addition salts thereof; and with the proviso that any chemical group (including any nucleobase), which is reactive under the conditions prevailing in oligonucleotide synthesis, is optionally functional group protected.

170. (previously presented) A nucleoside analogue according to any of the claim 169, wherein B is selected from nucleobases.

171. (previously presented) A nucleoside analogue according to claim 170, wherein B is selected from adenine and guanine thymine, cytosine uracil purine, xanthine, diaminopurine, 8-oxo-N⁶-methyladenine, 7-deazaxanthine, 7-deazaguanine, N⁴,N⁴-ethanocytosin, N⁶,N⁶-ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C³-C⁶)-alkynylcytosine, 2,6-diaminopyrimidine, 2,6-diaminopyrazine, 1-methyl-pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione, 1-methyl-pyrazolo[4,3-

Application No.: 10/208,650

9

Docket No.: 49165C3(71994)

d]pyrimidine-5,7(4H,6H)-dione, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanin, and inosine.

172. (previously presented). A kit for the isolation, purification, amplification, detection, identification, quantification, or capture of natural or synthetic nucleic acids, the kit comprising a reaction body and one or more LNAs as defined in claim 157.

173. (previously presented) A nucleic acid compound comprising the nucleoside analogue of claim 157.

174. (previously presented) The nucleoside analogue of claim 169, wherein Q* represents an activation group for -OH, -SH, and -NH(R^H).

175. (previously presented) The nucleoside analogue of claim 169, wherein said activation group is an optionally substituted phosphoramidite.

176. (previously presented) The nucleoside analogue of claim 169, wherein the nucleoside analogue is a 3'-phosphoramidite derivative.

177. (previously presented) The nucleoside analogue of claim 176, wherein the nucleoside analogue is an O-phosphoramidite.


178. (previously presented) The nucleoside analogue of claim 177, wherein the O-phosphoramidite is N,N-diisopropyl-O-(2-cyanoethyl)phosphoramidite.

179. (previously presented) A nucleoside analogue of the general formula IIa.

Application No.: 10/208,650

10

Docket No.: 49165C3(71994)



IIa

wherein X is -O-;

B is selected from nucleobases, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands;

R^{3*} is a group Q*;

each of Q and Q* is independently selected from hydrogen, azido, halogen, cyano, nitro, hydroxy, Prot-O-, Act-Q-, mercapto, Prot-S-, Act-S-, C₁₋₆-alkylthio, amino, Prot-N(R^H)-, Act-N(R^H)-, mono- or di(C₁₋₆-alkyl)amino, optionally substituted C₁₋₆-alkoxy, optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆-alkenyl, optionally substituted C₂₋₆-alkenyloxy, optionally substituted C₂₋₆-alkynyl, optionally substituted C₂₋₆-alkynyloxy, monophosphate, diphosphate, triphosphate, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, ligands, carboxy, sulphono, hydroxymethyl, Prot-O-CH₂-, Act-O-CH₂-, aminomethyl, Prot-N(R^H)-CH₂-, Act-N(R^H)-CH₂-, carboxymethyl, sulphonomethyl, where Prot is a protection group for -OH, -SH, and -NH(R^H), respectively, Act is an activation group for -OH, -SH, and -NH(R^H), respectively, and R^H is selected from hydrogen and C₁₋₆-alkyl;

R^{2*} and R^{4*} together designate a biradical selected from the following group:

- (a) $-(CR^*R^*)_r-O-(CR^*R^*)_s-$ wherein r is 0 (zero) and s is greater than 1, or s is 0 (zero) and r is greater than 1,

and further wherein each R* is independently selected from hydrogen, halogen, hydroxy, mercapto, amino, optionally substituted C₁₋₆-alkoxy, optionally substituted C₁₋₆-alkyl, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands;

Application No.: 10/208,650

11


Docket No.: 49165C3(71994)

each of the substituents R^{1*} , R^2 , R^3 , R^5 , and R^{5*} is independently selected from hydrogen, optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, hydroxy, C_{1-6} -alkoxy, C_{2-6} -alkenyloxy, carboxy, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkylcarbonyl, formyl, amino, mono- and di(C_{1-6} -alkyl)amino, carbamoyl, mono- and di(C_{1-6} -alkyl)-amino-carbonyl, C_{1-6} -alkyl-carbonylamino, carbamido, azido, C_{1-6} -alkanoyloxy, sulphonyl, sulphanyl, C_{1-6} -alkylthio, DNA intercalators, photochemically active groups, thermochemically active groups, chelating groups, reporter groups, and ligands, and halogen;

and basic salts and acid addition salts thereof;

and with the proviso that any chemical group (including any nucleobase), which is reactive under the conditions prevailing in oligonucleotide synthesis, is optionally functional group protected.

180. (previously presented) The nucleoside analogue of claim 157, wherein the analogue is represented by the following structure:



B = adenine, guanine, thymine, 5-methyl-cytosine, cytosine, uracil, 2,6-diaminopurine

181. (previously presented) The nucleoside analogue of claim 180, wherein the analogue is one of the following specific compounds:

- a) (1*R*,5*R*,7*R*,8*S*)-8-hydroxy-5-(hydroxymethyl)-7-(adenin-9-yl)-2,6-dioxabicyclo[3.2.1]octane,
- b) (1*R*,5*R*,7*R*,8*S*)-8-hydroxy-5-(hydroxymethyl)-7-(guanin-9-yl)-2,6-dioxabicyclo[3.2.1]octane,


Application No.: 10/208,650

12

Docket No.: 49165C3(71994)

- c) (1*R*,5*R*,7*R*,8*S*)-8-hydroxy-5-(hydroxymethyl)-7-(thymine-1-yl)-2,6-dioxabicyclo[3.2.1]octane,
d) (1*R*,5*R*,7*R*,8*S*)-8-hydroxy-5-(hydroxymethyl)-7-(5-methyl-cytosine-1-yl)-2,6-dioxabicyclo[3.2.1]octane,
e) (1*R*,5*R*,7*R*,8*S*)-8-hydroxy-5-(hydroxymethyl)-7-(cytosine-1-yl)-2,6-dioxabicyclo[3.2.1]octane,
f) (1*R*,5*R*,7*R*,8*S*)-8-hydroxy-5-(hydroxymethyl)-7-(uracil-1-yl)-2,6-dioxabicyclo[3.2.1]octane;
and
g) (1*R*,5*R*,7*R*,8*S*)-8-hydroxy-5-(hydroxymethyl)-7-(2,6-diaminopurine-9-yl)-2,6-dioxabicyclo[3.2.1]octane.

182. (previously presented) The nucleoside analogue of claim 157, wherein the analogue is represented by the following structure:



B = adenine, guanine, thymine, 5-methyl-cytosine, cytosine, uracil, 2,6-diaminopurine

Claim 183. (currently amended) The nucleoside analogue of claim ~~182~~ 157, wherein the analogue is one of the following specific compounds:

- a) (1*R*,3*R*,4*S*,7*R*)-7-hydroxy-1-(hydroxymethyl)-3-(adenine-9-yl)-2,5-dioxabicyclo[2.2.1]heptane,
b) (1*R*,3*R*,4*S*,7*R*)-7-hydroxy-1-(hydroxymethyl)-3-(guanine-9-yl)-2,5-dioxabicyclo[2.2.1]heptane,
c) (1*R*,3*R*,4*S*,7*R*)-7-hydroxy-1-(hydroxymethyl)-3-(thymine-1-yl)-2,5-dioxabicyclo[2.2.1]heptane,
d) (1*R*,3*R*,4*S*,7*R*)-7-hydroxy-1-(hydroxymethyl)-3-(5-methyl-cytosine-1-yl)-2,5-dioxabicyclo[2.2.1]heptane,

Application No.: 10/208,650

13


Docket No.: 49165C3(71994)

e) (1*R*,3*R*,4*S*,7*R*)-7-hydroxy-1-(hydroxymethyl)-3-(cytosin-1-yl)-2,5-dioxabicyclo[2.2.1]heptane,

f) (1*R*,3*R*,4*S*,7*R*)-7-hydroxy-1-(hydroxymethyl)-3-(uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane;
and

g) (1*R*,3*R*,4*S*,7*R*)-7-hydroxy-1-(hydroxymethyl)-3-(2,6-diaminopurin-9-yl)-2,5-dioxabicyclo[2.2.1]heptane.

184 (previously presented). A nucleoside analogue according to claim 158, having the general formula IIa



wherein the substituents Q, B, R^{1*}, R², R^{2*}, R³, R^{3*}, R^{4*}, R⁵, and R^{5*} are as defined in claim 158 provided the nucleoside analogue has a configuration other than β-D.

185. (previously presented) A method of preparing an LNA modified oligonucleotide (an oligomer) comprising making the oligonucleotide with the LNA of Claim 157.

186 (previously presented) The method of claim 185, wherein the LNA modified oligonucleotide comprises normal nucleosides.

187 (previously presented). A nucleoside analogue according to claim 160, wherein each of the substituents R^{1*}, R², R³, R^{3*}, and R⁵, R^{5*}, which are present and not involved in Q^{*} designate hydrogen.

188 (previously presented). A nucleoside analogue according to claim 160, wherein R^{3*} designates P^{*}.

189 (previously presented). A nucleoside analogue according to claim 161, wherein R^{3*} designates P^{*}.

Application No.: 10/208,650

14

Docket No.: 49165C3(71994)


REMARKS

Applicants request that the present amendment under 37 CFR §1.312 be entered prior to issuance of the above-captioned patent application. The amendment is intended to address an inadvertent typographical error. Specifically, Applicants have amended claim 183 to change dependency from 182 to claim 157. The amendment is not intended to address any matter related to patentability.

Applicants believe that no fee is required to consider and enter the instant amendment. However, if for any reason a fee is deemed necessary, the USPTO is hereby authorized and requested to charge Deposit Account No. 04-1105 for such fee.

Dated: December 20, 2004

Respectfully submitted,

By 
Robert L. Buchanan
Registration No.: 40,927
EDWARDS & ANGELL, LLP
P. O. Box 55874
Boston, Massachusetts 02205
(617) 438-4444
Attorneys for Applicant

#470917

Please type a plus sign (+) inside this box -

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number	09/925,673
Filed	August 9, 2001
First Named Inventor	Masakatsu KANEKO
Group Art Unit	1623
Examiner Name	Howard Owens, Jr.
Attorney Docket Number	01376CIP/HG

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Exam. Initials ¹	Cite No ²	Document Number	Kind Code ²	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion
		6,670,461	B1	WENGEL et al.	12-30-2003	
		2002/0068708	A1	WENGEL et al.	06-06-2002	
		2003/0134808	A1	WENGEL et al.	07-17-2003	
		2003/0144231	A1	WENGEL et al.	07-31-2003	

FOREIGN PATENT DOCUMENTS

Exam. Initials ¹	Cite No ²	Office ³	Document Number ⁴	Kind Code ⁵	Name of Patentee or Applicant	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶


Examiner
SignatureDate
Considered

* EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.

DATE MAILED: AUGUST 17, 2004

Docket No.: 01376CIP/HG
Ser. No. : 09/925,673
Applicants: Masakatsu KANEKO et al.



RECEIPT ACKNOWLEDGED:
REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL (in duplicate);
AMENDMENT; INFORMATION DISCLOSURE STATEMENT; FORM PTO/SB/08A AND
COPIES OF PUBLS. IDENTIFIED THEREIN; REQUEST FOR ACKNOWLEDGMENT OF
(1) APPLICANTS' CLAIM FOR PRIORITY UNDER 35 USC 119 AND () RECEIPT
CERTIFIED COPY OF PRIORITY DOCUMENT; CHECKS 5770 (RCE FILING FEE,
CHECK NO. 95338) AND 586 (EXTRA IND. CLAIM, CHECK NO. 95339)

EXPRESS LABEL EV 512 419 014 US
DATE OF DEPOSIT: August 17, 2004
DUE: Nov. 12, 2004

RSB/ddf